However, based on these early results, it does appear that APOE4+ AD patients may possess relatively more NFTs in the medial temporal lobe, most notably in the entorhinal cortex, while APOE4− AD patients may possess more NFTs in other cortical regions, such as the frontal and parietal lobes. The gene discussed is APOE; the disease is Alzheimer disease.